Susana Rocha

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9190267/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Fluctuations in C-reactive protein concentration and neutrophil activation during normal human pregnancy. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2005, 123, 46-51.	1.1	124
2	Interleukin (IL)-22, IL-17, IL-23, IL-8, vascular endothelial growth factor and tumour necrosis factor-α levels in patients with psoriasis before, during and after psoralen-ultraviolet A and narrowband ultraviolet B therapy. British Journal of Dermatology, 2010, 163, 1282-1290.	1.5	120
3	Câ€reactive protein and leucocyte activation in psoriasis <i>vulgaris</i> according to severity and therapy. Journal of the European Academy of Dermatology and Venereology, 2010, 24, 789-796.	2.4	107
4	Circulating adipokine levels in Portuguese patients with psoriasis <i>vulgaris</i> according to body mass index, severity and therapy. Journal of the European Academy of Dermatology and Venereology, 2010, 24, 1386-1394.	2.4	104
5	Effects of olive oil polyphenols on erythrocyte oxidative damage. Molecular Nutrition and Food Research, 2009, 53, 609-616.	3.3	95
6	The effect of green tea in oxidative stress. Clinical Nutrition, 2006, 25, 790-796.	5.0	92
7	Inflammation, T-Cell Phenotype, and Inflammatory Cytokines in Chronic Kidney Disease Patients Under Hemodialysis and its Relationship to Resistance to Recombinant Human Erythropoietin Therapy. Journal of Clinical Immunology, 2008, 28, 268-275.	3.8	77
8	Inflammatory Disturbances in Preeclampsia: Relationship between Maternal and Umbilical Cord Blood. Journal of Pregnancy, 2012, 2012, 1-10.	2.4	68
9	Circulating levels of adiponectin, oxidized LDL and C-reactive protein in Portuguese patients with psoriasis vulgaris, according to body mass index, severity and duration of the disease. Journal of Dermatological Science, 2009, 55, 202-204.	1.9	53
10	Peroxiredoxin 2, glutathione peroxidase, and catalase in the cytosol and membrane of erythrocytes under H ₂ O ₂ -induced oxidative stress. Free Radical Research, 2015, 49, 990-1003.	3.3	53
11	Powerful Protective Role of 3,4-Dihydroxyphenylethanolâ^'Elenolic Acid Dialdehyde against Erythrocyte Oxidative-Induced Hemolysis. Journal of Agricultural and Food Chemistry, 2010, 58, 135-140.	5.2	52
12	Effects of Chitooligosaccharides on Human Red Blood Cell Morphology and Membrane Protein Structure. Biomacromolecules, 2008, 9, 3346-3352.	5.4	51
13	Neutrophil Activation and Resistance to Recombinant Human Erythropoietin Therapy in Hemodialysis Patients. American Journal of Nephrology, 2008, 28, 935-940.	3.1	42
14	Hepcidin Serum Levels and Resistance to Recombinant Human Erythropoietin Therapy in Haemodialysis Patients. Acta Haematologica, 2009, 122, 226-229.	1.4	41
15	Presence of cytosolic peroxiredoxin 2 in the erythrocyte membrane of patients with hereditary spherocytosis. Blood Cells, Molecules, and Diseases, 2008, 41, 5-9.	1.4	38
16	Role of Prohepcidin, Inflammatory Markers and Iron Status in Resistance to rhEPO Therapy in Hemodialysis Patients. American Journal of Nephrology, 2008, 28, 677-683.	3.1	36
17	Psoriasis Therapy and Cardiovascular Risk Factors. American Journal of Clinical Dermatology, 2010, 11, 423-432.	6.7	36
18	Fetal lipoprotein changes in preâ€eclampsia. Acta Obstetricia Et Gynecologica Scandinavica, 2008, 87, 628-634	2.8	35

SUSANA ROCHA

#	Article	IF	CITATIONS
19	Cross-Talk between Inflammation, Coagulation/Fibrinolysis and Vascular access in Hemodialysis Patients. Journal of Vascular Access, 2008, 9, 248-253.	0.9	33
20	Fetal and maternal angiogenic/anti-angiogenic factors in normal and preeclamptic pregnancy. Growth Factors, 2009, 27, 345-351.	1.7	31
21	Linkage of cytosolic peroxiredoxin 2 to erythrocyte membrane imposed by hydrogen peroxide-induced oxidative stress. Blood Cells, Molecules, and Diseases, 2009, 43, 68-73.	1.4	31
22	Adiponectin and markers of metabolic syndrome in obese children and adolescents: impact of 8-mo regular physical exercise program. Pediatric Research, 2014, 76, 159-165.	2.3	26
23	Erythrocyte membrane protein destabilization <i>versus</i> clinical outcome in 160 Portuguese Hereditary Spherocytosis patients. British Journal of Haematology, 2010, 149, 785-794.	2.5	25
24	Protein deficiency balance as a predictor of clinical outcome in hereditary spherocytosis. European Journal of Haematology, 2005, 74, 374-380.	2.2	24
25	Biochemical and Cellular Changes in Leukocyte-Depleted Red Blood Cells Stored for Transfusion. Transfusion Medicine and Hemotherapy, 2015, 42, 46-51.	1.6	22
26	Green tea consumption improves plasma lipid profiles in adults. Nutrition Research, 2006, 26, 604-607.	2.9	21
27	The effect of olive leaf supplementation on the constituents of blood and oxidative stability of red blood cells. Journal of Functional Foods, 2014, 9, 271-279.	3.4	21
28	Leukocyte Count versus C-Reactive Protein Levels in Obese Portuguese Patients Aged 6-12 Years Old. The Open Biochemistry Journal, 2010, 4, 72-76.	0.5	21
29	Relationship between maternal and cord blood hemostatic disturbances in preeclamptic pregnancies. Thrombosis Research, 2008, 123, 219-224.	1.7	20
30	Altered Erythrocyte Membrane Protein Composition in Chronic Kidney Disease Stage 5 Patients under Haemodialysis and Recombinant Human Erythropoietin Therapy. Blood Purification, 2008, 26, 267-273.	1.8	18
31	Erythropoietin levels in the different clinical forms of hereditary spherocytosis. British Journal of Haematology, 2005, 131, 534-542.	2.5	17
32	Changes in Red Blood Cells Membrane Protein Composition during Hemodialysis Procedure. Renal Failure, 2008, 30, 971-975.	2.1	16
33	Erythrocyte changes in preeclampsia: relationship between maternal and cord blood erythrocyte damage. Journal of Perinatal Medicine, 2009, 37, 19-27.	1.4	16
34	Complementary markers for the clinical severity classification of hereditary spherocytosis in unsplenectomized patients. Blood Cells, Molecules, and Diseases, 2011, 46, 166-170.	1.4	16
35	Erythroid Disturbances Before and After Treatment of Portuguese Psoriasis Vulgaris Patients. American Journal of Clinical Dermatology, 2012, 13, 37-47.	6.7	15
36	Long Pentraxin 3 as a Broader Biomarker for Multiple Risk Factors in End-Stage Renal Disease: Association with All-Cause Mortality. Mediators of Inflammation, 2019, 2019, 1-12.	3.0	15

Susana Rocha

#	Article	IF	CITATIONS
37	The Protective Role of Adiponectin for Lipoproteins in End-Stage Renal Disease Patients: Relationship with Diabetes and Body Mass Index. Oxidative Medicine and Cellular Longevity, 2019, 2019, 1-11.	4.0	15
38	Interleukin 6 (rs1800795) and pentraxin 3 (rs2305619) polymorphisms-association with inflammation and all-cause mortality in end-stage-renal disease patients on dialysis. Scientific Reports, 2021, 11, 14768.	3.3	13
39	Linkage of typically cytosolic peroxidases to erythrocyte membrane – A possible mechanism of protection in Hereditary Spherocytosis. Biochimica Et Biophysica Acta - Biomembranes, 2020, 1862, 183172.	2.6	11
40	Doping Polysulfone Membrane with Alphaâ€Tocopherol and Alphaâ€Lipoic Acid for Suppressing Oxidative Stress Induced by Hemodialysis Treatment. Macromolecular Bioscience, 2020, 20, 2000046.	4.1	11
41	Cell-free DNA as a marker for the outcome of end-stage renal disease patients on haemodialysis. CKJ: Clinical Kidney Journal, 2021, 14, 1371-1378.	2.9	11
42	Band 3 Profile as a Marker of Erythrocyte Changes in Chronic Kidney Disease Patients. The Open Clinical Chemistry Journal, 2008, 1, 57-63.	0.7	11
43	Hepcidin and diabetes are independently related with soluble transferrin receptor levels in chronic dialysis patients. Renal Failure, 2019, 41, 662-672.	2.1	10
44	Hereditary spherocytosis and the (TA)nTAA polymorphism of UGT1A1 gene promoter region—A comparison of the bilirubin plasmatic levels in the different clinical forms. Blood Cells, Molecules, and Diseases, 2010, 44, 117-119.	1.4	7
45	Inflammatory biomarkers in staging of chronic kidney disease: elevated TNFR2 levels accompanies renal function decline. Inflammation Research, 2022, 71, 591-602.	4.0	7
46	Erythropoiesis versus inflammation in Hereditary Spherocytosis clinical outcome. Clinical Biochemistry, 2011, 44, 1137-1143.	1.9	6
47	Recombinant human erythropoietin-induced erythropoiesis regulates hepcidin expression over iron status in the rat. Blood Cells, Molecules, and Diseases, 2016, 59, 63-70.	1.4	6
48	Coexistence of congenital red cell pyruvate kinase and band 3 deficiency. International Journal of Laboratory Hematology, 2004, 26, 297-300.	0.2	5
49	IL-7 serum levels and lymphopenia in hemodialysis patients, non-responders to recombinant human erythropoietin therapy. Blood Cells, Molecules, and Diseases, 2008, 41, 134-135.	1.4	4
50	DMT1 (NRAMP2/DCT1) Genetic Variability and Resistance to Recombinant Human Erythropoietin Therapy in Chronic Kidney Disease Patients under Haemodialysis. Acta Haematologica, 2008, 120, 11-13.	1.4	4
51	Elastase release during the hemodialysis procedure seems to induce changes in red blood cell membrane proteins. Hemodialysis International, 2011, 15, 429-431.	0.9	4
52	Bilirubin Levels and Redox Status in a Young Healthy Population. Acta Haematologica, 2013, 130, 57-60.	1.4	4
53	Influence of the 6-month physical activity programs on renal function in obese boys. Pediatric Research, 2018, 83, 1011-1015.	2.3	3
54	<i>In vitro</i> studies with â€~acatalasemicâ€like' erythrocytes and hydrogen peroxide: attention to the formation of lysis resistant erythrocytes. International Journal of Laboratory Hematology, 2010, 32, 127-131.	1.3	2

Susana Rocha

#	Article	IF	CITATIONS
55	Subpopulations of High-Density Lipoprotein: Friends or Foes in Cardiovascular Disease Risk in Chronic Kidney Disease?. Biomedicines, 2021, 9, 554.	3.2	2
56	Interplay between Erythrocyte Peroxidases and Membrane. , 0, , .		2
57	SP342HEPCIDIN-25 AND TREATMENT WITH ERYTHROPOIESIS STIMULATING AGENTS ARE INDEPENDENTLY RELATED WITH ERYTHROPOIESIS IN CHRONIC HEMODIALYSIS PATIENTS. Nephrology Dialysis Transplantation, 2018, 33, i460-i460.	0.7	1
58	Cellular and Molecular Pathways Underlying the Nephrotoxicity of Gadolinium. Toxicological Sciences, 2022, 186, 134-148.	3.1	1
59	Letter to the Editor: A potential mechanism for the pathogenesis of psoriasis <i>vulgaris</i> . International Journal of Dermatology, 2013, 52, 1429-1432.	1.0	0
60	SP666MACHINE LEARNING IN PREDICTION OF VULNERABLE OR RESILIENT END-STAGE RENAL DISEASE PATIENTS. Nephrology Dialysis Transplantation, 2019, 34, .	0.7	0
61	SP637INFLAMMATION AND CELL-FREE DNA AS BIOMARKERS FOR THE OUTCOME OF END STAGE RENAL DISEASE PATIENTS. Nephrology Dialysis Transplantation, 2019, 34, .	0.7	0
62	SP543ASSOCIATION OF PTX3, NT-proBNP AND LEFT VENTRICULAR HYPERTROPHY IN PATIENTS ON DIALYSIS. Nephrology Dialysis Transplantation, 2019, 34, .	0.7	0
63	SP674IN DIALYSIS PATIENTS FUROSEMIDE THERAPY IS FAVORABLY RELATED WITH INFLAMMATORY RESPONSE, FIBRINOLYSIS, AND BIOMARKERS OF RESIDUAL RENAL FUNCTION. Nephrology Dialysis Transplantation, 2019, 34, .	0.7	0
64	FP725PENTRAXIN 3 IN END-STAGE RENAL DISEASE: MULTIPLE RISK BIOMARKER AND PREDICTOR OF ALL-CAUSE MORTALITY. Nephrology Dialysis Transplantation, 2019, 34, .	0.7	0
65	FP730EFFECTS OF STATINS THERAPY ON LDL SUBFRACTIONS AND INFLAMMATION, IN END-STAGE RENAL DISEASE PATIENTS ON DIALYSIS. Nephrology Dialysis Transplantation, 2019, 34, .	0.7	0
66	FP731LIPOIC ACID COATED POLYSULFONE FLAT SHEET MEMBRANE - NEW AP-PROACH TO REDUCE OXIDATIVE STRESS IN HAEMODIALYSED PATIENTS. Nephrology Dialysis Transplantation, 2019, 34, .	0.7	0
67	Ascorbic Acid as an Important Erythrocyte Antioxidant Defense in Patients with Non-immune Hemolytic Anemias – a preliminary study. Free Radical Biology and Medicine, 2020, 159, S28.	2.9	0
68	P1570INTERLEUKIN-6 (RS1800795) AND PENTRAXIN 3 (RS2305619) GENETIC POLYMORPHISMS AND THEIR RELATION WITH INFLAMMATION AND ALL-CAUSE MORTALITY IN ESRD PATIENTS ON DIALYSIS. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	0
69	P1531DIURETIC USE IN HEMODIALYSIS PATIENTS: BENEFIC ASSOCIATION WITH RESIDUAL RENAL FUNCTION AND ALL-CAUSE MORTALITY. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	0
70	P1581IMPACT OF ACHIEVING LDL CHOLESTEROL LOWER THAN 100 MG/DL WITH STATINS, ON LIPID PROFILE AND INFLAMMATION IN END-STAGE RENAL DISEASE PATIENTS. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	0
71	P1263ASSOCIATION OF LEFT VENTRICULAR HYPERTROPHY AND ADIPOCYTOKINES IN PATIENTS ON DIALYSIS. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	0
72	P0739PANEL OF SENSITIVE BIOMARKERS OF THE PRIMARY RESPONSE TO RENAL INJURY FOR AN EARLY DIAGNOSIS OF CHRONIC KIDNEY DISEASE. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	0

SUSANA ROCHA

#	Article	IF	CITATIONS
73	MO1046DOPING POLYSULFONE DIALYSIS MEMBRANES WITH HUMAN NEUTROPHIL ELASTASE INHIBITORS - A PILOT STUDY. Nephrology Dialysis Transplantation, 2021, 36, .	0.7	0
74	MO810INTERLEUKIN-6 (-174G/C) POLYMORPHISM, RS1800795, IN ESRD PATIENTS' OUTCOME*. Nephrology Dialysis Transplantation, 2021, 36, .	0.7	0
75	MO472A PRELIMINARY STUDY OF POTENTIAL BIOMARKERS FOR EARLY DIAGNOSIS IN CHRONIC KIDNEY DISEASE. Nephrology Dialysis Transplantation, 2021, 36, .	0.7	0
76	MO735INTERPLAY BETWEEN GDF-15 AND LEFT VENTRICULAR HYPERTROPHY IN END-STAGE RENAL DISEASE PATIENTS ON DIALYSIS. Nephrology Dialysis Transplantation, 2021, 36, .	0.7	0
77	Effect of hemodialysis procedure in prohepcidin serum levels in regular hemodialysis patients. Clinical Nephrology, 2009, 71, 233-235.	0.7	0